BIOX CorporationTSX: BX

BIOX announces fourth quarter results

· Issued by BIOX Corporation via CNW

Key figures

  • Sales were $17,724,000 in Q4 2014 compared to $25,037,000 in Q4 2013
  • Operating loss was $2,245,000 in Q4 2014 compared to $1,390,000 in Q4 2013
  • Operating loss prior to non-cash items was $1,132,000 in Q4 2014 compared to operating income prior to non-cash items of $1,609,000 in Q4 2013
  • Net income was $1,433,000 in Q4 2014 compared to net loss of $1,014,000 in Q4 2013
  • Income per share was $0.04 in Q4 2014 compared to net loss per share of $0.02 in Q4 2013

On 6ix: 6ix.com/news/biox-announces-fourth-quarter-results

TSX symbol: BX

TORONTO, Dec. 12, 2014 /CNW/ - BIOX Corporation (BIOX) (TSX: BX), a renewable energy company, today announced its fiscal 2014 fourth quarter (Q4 2014) and year-end financial results for the three-month and twelve-month periods ended September 30, 2014.

Highlights

  • Production of methyl esters was 15.5 million litres for the three-month periods ended September 30, 2014 (Q4 2014), unchanged from the same period last year (Q4 2013)
  • Sales were $17,724,000 in Q4 2014 compared to $25,037,000 in Q4 2013
  • Operating loss was $2,245,000 in Q4 2014 compared to $1,390,000 in Q4 2013
  • Operating loss prior to non-cash items(1) was $1,132,000 in Q4 2014 compared to operating income prior to non-cash items of $1,609,000 in Q4 2013
  • Net income was $1,433,000 in Q4 2014 compared to net loss of $1,014,000 in Q4 2013
  • Income per share was $0.04 in Q4 2014 compared to net loss per share of $0.02 in Q4 2013

"Our production facility in Hamilton continues to operate well within our target range and we are seeing growing demand for biodiesel in the Ontario market," said Kevin Norton, Chief Executive Officer of BIOX. "Unfortunately, the renewable fuels market in the U.S. offers less clarity. The delay in the final Renewable Volume Obligation for 2014 continues to negatively impact product pricing and RIN values. While the House of Representative recently approved a tax bill that includes a retroactive reinstatement of the U.S. biodiesel tax incentive, the bill still requires Senate and Presidential approvals. Until these structural issues are addressed the margins earned by producers will continue to be negatively impacted. The cost savings measures we deployed earlier this year and the greater emphasis we have placed on the Canadian market are meant to help ensure the sustainability of the business while we await greater clarity on the outlook within the U.S. market."

Financial Highlights

Sales were $17.7 million and $67.5 million, respectively, for the three-month and twelve-month periods ended September 30, 2014, compared with $25.0 million and $75.2 million for the corresponding periods in 2013. The change was due to lower revenue per litre of biodiesel sold due to market conditions in both the three-month and full year periods compared to the corresponding periods in 2013 as well as from the reinstatement of the biodiesel tax incentive and alternative fuel credit which allowed the company to recognize approximately $7.8 million in refundable tax credits in Q2 2013.

Direct expenses were $17.8 million and $67.4 million, respectively, for the three-month and twelve-month periods ended September 30, 2014, compared with $22.3 million and $62.3 million for the corresponding periods in 2013.  The decrease in the three-month period was due to lower direct costs per litre primarily due to a decrease in feedstock costs. The increase in the twelve-month period was the result of higher sales volumes for fiscal 2014 compared to fiscal 2013.

General and administrative expenses were $1.1 million and $5.1 million, respectively, for the three-month and twelve-month periods ended September 30, 2014, compared with $1.2 million and $5.3 million for the corresponding periods in 2013.

Operating loss was $2.2 million and $14.7 million, respectively, for the three-month and twelve-month periods ended September 30, 2014, compared with $1.4 million and $2.2 million for the corresponding periods in 2013. The increased losses for the three-month and full year periods in 2014 were primarily due to the expiry in December 2013 of the US$1.00 per US gallon U.S. biodiesel tax incentive that was in effect in calendar 2013, which resulted in a stronger biodiesel pricing environment during the 2013 periods.

Operating loss prior to non-cash items was $1.1 million and $5.0 million, respectively, for the three-month and twelve-month periods ended September 30, 2014, compared to operating income prior to non-cash items of $1.6 million and $5.4 million in the corresponding periods last year.

Net income was $1.4 million or $0.04 per share and net loss was $26.7 million or $0.58 per share, respectively, for the three-month and twelve-month periods ended September 30, 2014, compared with net loss of $1.0 million or $0.02 per share and $2.8 million or $0.06 per share for the corresponding periods in 2013. The increase in net income for the three-month period was the result of an increase of $4.1 million in the tax asset compared with an increase of $0.8 million in the corresponding period in 2013. The increase in net loss for fiscal 2014 was primarily due to significantly lower gross margins achieved in fiscal 2014 as well as an impairment charge in Q2 2014 on non-current assets based on a decrease in the recoverable amount for these assets due to weakness in the biodiesel market that reduced the Company's expectations for discounted future cash flows for operations.

As at September 30, 2014, BIOX's available cash position amounted to $7.2 million, which consisted of cash and cash equivalents and short-term investments, compared with $15.9 million at September 30, 2013. Working capital as of September 30, 2014, was $8.4 million. The Company believes that its future cash flow from operations combined with its current financial resources should be sufficient to enable BIOX to meet its ongoing requirements for capital expenditures and working capital requirements.

As at September 30, 2014 and December 12, 2014, the Company had 45,710,967 common shares outstanding, as well as outstanding stock options to purchase 2,555,000 common shares and share purchase warrants to acquire up to 1,982,143 common shares.

Outlook

The value of biodiesel and Biomass-based Diesel Renewable Identification Numbers or "(RINs)" continue to be negatively impacted due to the delay in finalizing the 2014 and 2015 Renewable Volume Obligation (RVO). On November 21, 2014, the U.S. Environmental Protection Agency (EPA) announced that it would not complete the final rule for 2014 until sometime in 2015.  2014 RINs traded at approximately $0.625 (or $0.9375 per U.S. gallon) as of December 11th, 2014. The final announcement of the RVO levels for 2014 and 2015 will be an important signal for the sustainability of the biodiesel industry in the U.S.

At the same time, the industry is awaiting clarity on the U.S. biodiesel tax incentive which provides parties that blend biodiesel with petroleum diesel with a U.S. $1.00 refundable tax credit for each U.S. gallon of biodiesel blended in the U.S. The incentive expired for the third time on December 31, 2013.  On December 3, 2014, the U.S. House of Representatives voted overwhelmingly to pass a package of tax incentives retroactively for 2014, including the $1 per U.S. gallon biodiesel tax incentive.  The bill requires U.S. Senate and Presidential approval prior to becoming law. Management believes that any reinstatement of the biodiesel tax incentive could be delayed until the end of the year or early in 2015 and that it is possible the program will not be reinstated at all.  Uncertainty surrounding the renewal of the biodiesel tax incentive could cause continued short term confusion in the market and pricing volatility.

While BIOX has historically sold the majority of its product into the U.S. market, the implementation of the Canadian regulations significantly increase the accessible market for its product in Canada. Furthermore, the implementation of a renewable diesel mandate in Ontario on April 1, 2014, provides BIOX with market certainty in its local region, which supports the significant capital investment that it made in the Hamilton facility. Once fully implemented, the regulation requires the use of an estimated 240 million litres of bio-based diesel per annum on an average GHG adjusted volume basis.

BIOX's inter-terminal pipeline and supply agreement with Shell is an example of how the Company can directly service primary suppliers with a secure supply of biodiesel under the new Canadian and Ontario regulations by the most efficient possible logistics. The supply of biodiesel under this agreement has the potential to become a significant portion of BIOX's Hamilton production given the implementation of the Ontario mandate and as the Canadian Renewable Fuel Content Regulations extend eastward into Québec and the Atlantic provinces.

BIOX continues to pursue growth strategies that would expand its business through increasing the volume of biodiesel it produces, controls and distributes in strategic locations throughout North America.

Notice of Conference Call

BIOX will hold a conference call on Monday, December 15, 2014, at 9:00 a.m. ET hosted by Mr. Kevin Norton, Chief Executive Officer, and Mr. Chris Clinning, Executive Vice President and Chief Financial Officer, to discuss BIOX's financial results and corporate developments. To access the conference call by telephone, dial (647) 427-7450 or (888) 231-8191. To access the telephone replay, dial (416) 849-0833 or
(855) 859-2056 and enter reservation number 46968385.

1) Note: Non-IFRS Measures.  Operating income prior to non-cash items is defined as operating income or loss less production facility depreciation and amortization, and less depreciation and amortization of furniture, equipment and intangibles. Management uses this measurement to monitor the operating cash flow of BIOX's business and believes this information is useful supplemental information to a reader of financial statements. This measurement may not be comparable to similar measures presented by other issuers.  Investors are cautioned that operating income (loss) prior to non-cash items should not be construed as an alternative to net income (loss) determined in accordance with IFRS as an indicator of BIOX's performance.

Reconciliation of Non-IRFS Measures

The following table presents a reconciliation of operating (loss) income prior to non-cash items to net income (loss) for the three-months and years ended September 30, 2014 and 2013:

(in thousands)

Three months ended
September 30

Year ended
September 30

2014

2013

2014

2013

$

$

$

$

Operating (loss) income before non-cash items

(1,132)

1,609

(4,979)

5,362

Deduct:

Production facility depreciation
and amortization

(1,040)

(1,035)

(4,132)

(4,037)

Depreciation and amortization
of equipment and intangible assets

(52)

(88)

(323)

(370)

Share-based compensation

(21)

(99)

(231)

(367)

Provision for unutilized tank storage

--

(1,777)

(4,999)

(2,810)

Operating loss

(2,245)

(1,390)

(14,664)

(2,222)

Deferred income tax recovery

4,105

795

4,105

777

Impairment of non-current assets

--

--

(15,197)

--

Other income and expenses

(427)

(419)

(936)

(1,396)

Net income (loss)

1,433

(1,014)

(26,692)

(2,841)

About BIOX Corporation
BIOX is a renewable energy company that owns and operates a 67 million litre per year continuous flow biodiesel production facility in Hamilton, Ontario. BIOX has an innovative, proprietary and patented production process that is capable of producing the highest quality, renewable, clean burning and biodegradable biodiesel fuel utilizing a variety of feedstocks - from pure seed oils to animal fats to recovered vegetable oils with no change to the production process. BIOX's high quality biodiesel fuel meets North American (ASTM D-6751) quality standards.

Forward-looking Statements
Certain statements in this press release constitute "forward-looking" statements that involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, objectives or achievements of BIOX, or industry results, to be materially different from any future results, performance, objectives or achievements expressed or implied by such forward-looking statements. Such statements relate to, among other things, BIOX's long-term expectations for the biodiesel market in light of current market conditions, the implementation of an Ontario biodiesel mandate and its effect on BIOX, the significance of sales under the supply agreement with Shell, and the ability of BIOX to realize on its cost savings programs. These statements reflect BIOX's current views regarding future events and operating performance, are based on information currently available to BIOX, and speak only as of the date of this press release. These forward-looking statements involve a number of risks, uncertainties and assumptions and should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether or not such performance or results will be achieved. Those assumptions and risks include, but are not limited to, the fact that BIOX's results of operations and business outlook are highly dependent on a mix of legislation and producer payment programs and tax credits and upon commodity prices, which are subject to significant volatility and uncertainty. Many factors could cause the actual results, performance or achievements of BIOX to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including factors described in this press release and those discussed in BIOX's publicly available disclosure documents, as filed by BIOX on SEDAR (www.sedar.com) except as updated herein. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described in this press release as intended, planned, anticipated, believed, estimated or expected. Unless required by applicable securities law, BIOX does not intend and does not assume any obligation to update these forward-looking statements.To the extent any forward-looking statements herein constitute financial outlook, they were approved by management as of the date hereof and have been included to provide an understanding with respect to BIOX's financial performance and are subject to the same risks and assumptions referred to herein. There can be no assurance that the plans, intentions or expectations upon which these forward-looking statements are based will occur and readers are cautioned that any financial outlook information contained in this news release should not be used for purposes other than for which it is disclosed herein.

BIOX Corporation

Consolidated statements of comprehensive income (loss)

three and twelve month periods ended September 30

(Expressed in thousands of Canadian dollars, except share and per share amounts)

Three months ended

September 30,

Twelve months ended

September 30,

2014

2013

2014

2013

$

$

$

$

Revenue

17,724

25,037

67,547

75,246

Cost of sales

Direct expenses

17,791

22,259

67,426

62,301

Production facility depreciation and amortization

1,040

1,035

4,132

4,037

18,831

23,294

71,558

66,338

Gross margin

(1,107)

1,743

(4,011)

8,908

Operating expenses

General and administrative

1,065

1,169

5,100

5,306

Depreciation and amortization of equipment and intangible assets

52

88

323

370

Share-based compensation

21

99

231

367

Expansion planning and development

-

1,777

4,999

5,087

1,138

3,133

10,653

11,130

Operating loss

(2,245)

(1,390)

(14,664)

(2,222)

Other expenses

Impairment of non-current assets

-

-

15,197

-

Financing cost

317

285

1,240

1,232

Foreign exchange (gain) loss

127

155

(204)

248

444

440

16,233

1,480

Net loss before interest income and income taxes

(2,689)

(1,830)

(30,897)

(3,702)

Deferred income tax recovery

4,105

795

4,105

777

Interest income

17

21

100

84

Net income (loss) for the year

1,433

(1,014)

(26,692)

(2,841)

Other comprehensive loss

Foreign currency translation loss

(170)

(21)

(161)

(111)

Comprehensive income (loss)

1,263

(1,035)

(26,853)

(2,952)

Income (loss) per common share

Basic

0.04

(0.02)

(0.58)

(0.06)

Diluted

0.04

(0.02)

(0.58)

(0.06)

Weighted average number of common shares outstanding

Basic

45,710,967

45,748,691

45,717,889

45,748,691

Diluted

46,083,208

45,748,691

45,717,889

45,748,691

BIOX Corporation

Consolidated statements of changes in equity

years ended September 30

(Expressed in thousands of Canadian dollars)

Common share capital

Warrants

Equity

Accumulated
other
comprehensive

Total

Shares

Amount

reserve

reserve

income (loss)

Deficit

equity

#

$

$

$

$

$

$

Balance, October 1, 2012

45,748,691

167,787

3,151

2,559

20

(107,972)

65,545

Share-based compensation

-

-

-

367

-

-

367

Net loss

-

-

-

-

-

(2,841)

(2,841)

Foreign currency translation loss

-

-

-

-

(111)

-

(111)

Balance, September 30, 2013

45,748,691

167,787

3,151

2,926

(91)

(110,813)

62,960

Balance, October 1, 2013

45,748,691

167,787

3,151

2,926

(91)

(110,813)

62,960

Share-based compensation

-

-

-

231

-

-

231

Forfeiture of options

-

-

-

(192)

-

192

-

Share cancellation

(37,724)

(14)

-

-

-

-

(14)

Net loss

-

-

-

-

-

(26,692)

(26,692)

Foreign currency translation loss

-

-

-

-

(161)

-

(161)

Balance, September 30, 2014

45,710,967

167,773

3,151

2,965

(252)

(137,313)

36,324

BIOX Corporation

Consolidated statements of financial position

as at September 30

(Expressed in thousands of Canadian dollars)

2014

2013

$

$

Assets

Current assets

Cash and cash equivalents

7,212

15,909

Accounts receivable

2,621

5,839

Prepaid expenses

665

839

Inventory

7,078

5,143

17,576

27,730

Restricted cash

1,309

1,800

Property, plant and equipment

29,458

46,930

Intangible assets

515

912

Deferred income tax assets

14,381

10,276

63,239

87,648

Liabilities

Current liabilities

Accounts payable and other liabilities

6,028

6,300

Current portion of long-term debt

1,125

1,500

Current portion of finance leases

29

31

Current portion of provisions

2,010

2,434

9,192

10,265

Finance leases

28

34

Long-term debt

9,727

10,849

Provisions

7,968

3,540

26,915

24,688

Equity

Common share capital

167,773

167,787

Warrants reserve

3,151

3,151

Equity reserve

2,965

2,926

Accumulated other comprehensive loss

(252)

(91)

Deficit

(137,313)

(110,813)

36,324

62,960

63,239

87,648

BIOX Corporation

Consolidated statements of cash flows

years ended September 30

(Expressed in thousands of Canadian dollars)

2014

2013

$

$

Operating activities

Net loss

(26,692)

(2,841)

Add items not involving cash

Production facility depreciation and amortization

4,132

4,037

Depreciation and amortization of equipment and intangible assets

323

370

Financing costs

722

845

Provision for unutilized tank storage

3,682

2,434

Impairment of non-current assets

15,197

-

Income taxes paid

-

18

Unrealized foreign exchange gain

(356)

(166)

Share-based compensation

231

367

Accretion of asset retirement obligation

322

279

Deferred income tax asset

(4,105)

(777)

(6,544)

4,566

Net change in non-cash working capital balances

related to operations

1,553

8,542

(4,991)

13,108

Investing activities

Purchase of property, plant and equipment

(2,151)

(4,720)

Decrease in restricted cash

491

5,142

Share repurchase

(14)

-

(1,674)

422

Financing activities

Payments on finance leases

(34)

(45)

Proceeds from debt financing

-

2,415

Repayment of debt financing

(1,500)

(1,500)

Repayment of demand loan

-

(5,282)

Interest paid

(693)

(807)

(2,227)

(5,219)

Effect of exchange rate changes on cash held in foreign currency

195

55

Net (decrease) increase in cash and cash equivalents during the year

(8,697)

8,366

Cash and cash equivalents, beginning of year

15,909

7,543

Cash and cash equivalents, end of year

7,212

15,909

Supplemental information

Restricted Cash

1,309

1,800

SOURCE BIOX Corporation

BIOX Corporation, Chris Clinning, Executive Vice President & CFO, Phone: 905-521-8205 ext. 253, E-mail: cclinning@bioxcorp.com; Investor Relations, Ross Marshall, TMX Equicom, Phone: (416) 815-0700 ext. 238, E-mail: rmarshall@tmxequicom.comCopyright CNW Group 2014

View original source (CNW)BIOX Corporation on 6ix

Story so far

Earlier from BIOX

Later from BIOX

All BIOX news releases